Are angiotensin converting enzyme inhibitors and angiotensin receptor blockers becoming the treatment of choice in African-Americans?

被引:0
|
作者
Andrew Fenves
C. Venkata S. Ram
机构
来源
关键词
Angiotensin Converting Enzyme Inhibitor; Angiotensin Receptor Blocker; Telmisartan; Nisoldipine; Blood Pressure Goal;
D O I
暂无
中图分类号
学科分类号
摘要
African-American patients constitute a significant and important group who are at high risk for developing hypertension-related complications. The proportion of African-American patients succumbing to or suffering from cardiovascular, renal, and neurologic sequalae is unacceptably high. Therefore, it is extremely crucial to develop appropriate therapeutic strategies for this vital subset of our society. The renin-angiotensin system may play a role in the pathophysiology of hypertension-related diseases, and therefore drugs that block this system, ie, angiotensin converting enzyme inhibitors and angiotensin receptor blockers, may have a special indication for African-American patients. Although these drugs may not be the most efficacious agents in terms of blood pressure reduction, they have a major benefit in offering target organ protection and arresting disease progression in the African-Americans. Hence, contrary to the old notions, drugs blocking the renin-angiotension system have an important place in the management of hypertension and related disorders in African-American patients.
引用
收藏
页码:286 / 289
页数:3
相关论文
共 50 条
  • [31] Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan
    Stefano Omboni
    Massimo Volpe
    Advances in Therapy, 2019, 36 : 278 - 297
  • [32] Angiotensin II-receptor blockers: will they replace angiotensin-converting enzyme inhibitors in the treatment of hypertension?
    Kaplan, NM
    JOURNAL OF HUMAN HYPERTENSION, 2000, 14 (Suppl 1) : S87 - S90
  • [33] Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan
    Omboni, Stefano
    Volpe, Massimo
    ADVANCES IN THERAPY, 2019, 36 (02) : 278 - 297
  • [34] Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide
    Mamdani, Muhammad
    Gomes, Tara
    Greaves, Simon
    Manji, Selina
    Juurlink, David N.
    Tadrous, Mina
    Kennedy, Sidney H.
    Antoniou, Tony
    JAMA NETWORK OPEN, 2019, 2 (10)
  • [35] The Role of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Postangioplasty Restenosis
    Liu, Ying
    Carrey, Zev
    Aronow, Wilbert S.
    Alaie, Daruish
    Petrillo, Richard L.
    Frishman, William H.
    AMERICAN JOURNAL OF THERAPEUTICS, 2015, 22 (04) : e107 - e114
  • [36] Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in clinical practice
    Barrios, Vivencio
    Coca, Antonio
    Escobar, Carlos
    Enrique, Rosa
    Miguel Rincon, Luis
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2012, 10 (02) : 159 - 166
  • [37] Premorbid angiotensin converting enzyme inhibitors or angiotensin II receptor blockers in patients with sepsis
    Hasegawa, Daisuke
    Lee, Young Im
    Prasitlumkum, Narut
    Chopra, Lakshay
    Nishida, Kazuki
    Smith, Robert L.
    Sato, Ryota
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2022, 62 : 69 - 77
  • [38] The Different Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Mortality
    Mourad, Jean-Jacques
    MAYO CLINIC PROCEEDINGS, 2016, 91 (07) : 972 - 972
  • [39] Angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, and risk of appendicitis
    Mukamal, Kenneth J.
    Ghimire, Sanjay
    Pandey, Rudra
    Fiarman, Gale S.
    Gautam, Shiva
    ANNALS OF EPIDEMIOLOGY, 2012, 22 (10) : 747 - 750
  • [40] Cardiac Mortality in Users of Olmesartan, Angiotensin Receptor Blockers and Angiotensin Converting Enzyme Inhibitors
    Walker, Alec
    Liang, Caihua
    Clifford, Robin
    Parker, Crawford
    Feldman, Allen
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 192 - 193